Pioglitazone (AD-4833)

Catalog No.S2590 Synonyms: U 72107

For research use only.

Pioglitazone (AD-4833, U 72107) is a selective peroxisome proliferator-activated receptor-gamma (PPARγ) agonist, used to treat diabetes; A weak activator for full-length hPPARα, but not full-length hPPARδ.

Pioglitazone (AD-4833) Chemical Structure

CAS No. 111025-46-8

Selleck's Pioglitazone (AD-4833) has been cited by 20 publications

Purity & Quality Control

Choose Selective PPAR Inhibitors

Other PPAR Products

Biological Activity

Description Pioglitazone (AD-4833, U 72107) is a selective peroxisome proliferator-activated receptor-gamma (PPARγ) agonist, used to treat diabetes; A weak activator for full-length hPPARα, but not full-length hPPARδ.
Targets
PPARγ [2]
In vitro

Pioglitazone is metabolised mainly by CYP2C8 and to a lesser extent by CYP3A4 in vitro. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CV-1 NYKwTI4yTnWwY4Tpc44h[XO|YYm= M3zJWWlvKH[rdILvJJRz[W6|Y4LpdJRqd26jbDDhZ5RqfmG2aX;uJI9nKFCncn;4bZNwdWVicILvcIln\XKjdH;yJIFkfGm4YYTl[EBz\WOncITvdkBo[W2vYTCoVHBCWiliZYjwdoV{e2WmIHnuJGNXNTFiY3XscJMtKEWFNUC9NE43Qc7:TR?= NFvzR5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi96NUe2PVA4Lz56NUe2PVA4RC:jPh?=
3T3-L1 NYKwXXRiTnWwY4Tpc44h[XO|YYm= NHzLZoZG\m[nY4TpeoUh[2:wY3XueJJifGmxbjDmc5IhPTBnIHXubIFv[2WvZX70JI9nKGmwc4XsbY4ucW6mdXPl[EB1emmpbInj[ZJq\GViYXPjeY12dGG2aX;uJIlvKDOWMz3MNUBk\WyuczygSWM2OD1yLkG2{txO NIfpW|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi97NUm5NlQyLz57NUm5NlQyRC:jPh?=
CV-1 NWD5elB{TnWwY4Tpc44h[XO|YYm= Mn;oRYN1cX[jdHnvckBw\iCyZYLvfIl{d22nIIDyc4xq\mW{YYTvdkBi[3SrdnH0[YQhemWlZYD0c5Ih\2GvbXGgcYVie3W{ZXSgZpkhcW6mdXP0bY9vKG:oIEWwKUBw\iCvYYjpcZVuKGGua3HsbY5mKHCqb4PwbIF1[XOnIHHjeIl3cXS7LDD0doFve2[nY4Tpc44h[XO|YYmgbY4hS1ZvMTDj[YxteyxiRVO1NF0xNjV6OEi0{txO M3H1c|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzl6M{[2NlAoRjl6M{[2NlA9N2F-
CV-1 NE\xemRHfW6ldHnvckBie3OjeR?= NYrUZ3k6VWG6aX3hcEBz\XCxcoTldkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDldo95cXOxbXWgdJJwdGmoZYLheI9zKGGldHn2ZZRm\CC{ZXPldJRweiCpYX3tZUBI[Wx2IHPobY1memmlIHnuJJRz[W6|aXXueIx6KHS{YX7z[oVkfGWmIFPWMVEh[2WubIOgZpkh\nWwY4Tpc45idCCjc4PhfU4tKEWFNUC9NE42QM7:TR?= MoW0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF5MkC4OVQoRjFzN{KwPFU1RC:jPh?=
HEK293 NGj3b5JHfW6ldHnvckBie3OjeR?= MmXkRYdwdmm|dDDhZ5Rqfmm2eTDheEBRWEGUZ3HtcYEh\XiycnXzd4VlKGmwIFjFT|I6OyClZXzsd{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gdoVk\XC2b4KgbY51\XKjY4Tpc44hf2m2aDDzeIVzd2mmIILlZ4VxfG:{IHPvZYN1cX[jdH;yMVEh[nliRWnGVEBj[XOnZDDy[ZBwenSncjDn[Y5mKGG|c3H5 MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjZ6MEG1PUc,OTZ4OECxOVk9N2F-
HEK293 NInNTJZHfW6ldHnvckBie3OjeR?= NULDUW93SWexbnnzeEBi[3Srdnn0fUBifCCSUFHS[4FudWFiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhemWlZYD0c5IhcW62ZYLhZ5Rqd25id3n0bEBz\XSrbn;p[EBZNXKnY3XweI9zKGGucHjhJIJ6KEW\RmCgZoF{\WRicnXwc5J1\XJiZ3Xu[UBie3OjeR?= Moe1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ4OECxOVkoRjF4NkiwNVU6RC:jPh?=
CV1 NGTVNmVHfW6ldHnvckBie3OjeR?= NIOxVGZVemGwc3HjeIl3[XSrb36gc4YhWFCDUnfhcY1iKGmwIFPWNUBk\WyuczygSWM2OD1yLkW1{txO NXmyUVl7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[4NlE4PjlpPkG2PFIyPzZ7PD;hQi=>
Cos7 M3vhemZ2dmO2aX;uJIF{e2G7 MV:xOEBpenN? NHX4[ldVemGwc3HjeIl3[XSrb36gc4YhcHWvYX6gVHBCWmejbX3hJGxDTCCneIDy[ZN{\WRiaX6gZYZzcWOjbjDndoVmdiCvb37r[ZkhS2:|NzDj[YxteyClbz30doFve2[nY4Tl[EB4cXSqIH\1d4VlKEeDTEStSGJFKGGodHXyJFE1KGi{czDifUBFfWGuLVfsc{BNfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVA:OC5|zszN M1LZSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{C3PVgyLz5{MEOwO|k5OTxxYU6=
3T3L1 M{TmeGZ2dmO2aX;uJIF{e2G7 MV6xNFAhfW2xbD;M MknQTY5kemWjc3WgbY4hWFCDUnfhcY1iKG2UTlGgcIV3\Wy|IHnuJI1wfXOnIEPUN2wyKGOnbHzzJIF1KDFyMDD1cY9tN0xiYomgVnQuWEOU NEDn[lQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEO5NlY1PSd-MkCzPVI3PDV:L3G+
CHO MmfFSpVv[3Srb36gZZN{[Xl? MV3BZ5RqfmG2aX;uJI9nKEejbESteIFo\2WmIHj1cYFvKFCSQWLnZY1u[SCneIDy[ZN{\WRiaX6gR2hQKGOnbHzzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OD1yLkG0{txO M133O|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNkW2OFk1Lz5{ME[1OlQ6PDxxYU6=
HEK293T NX3KRVhpTnWwY4Tpc44h[XO|YYm= MUCxJJVO M1;DeVI1KGi{cx?= MkHrVIFzfGmjbDDh[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGDQRXJo[W2vYT3MRmQh\XiycnXzd4VlKGmwIFjFT|I6O1RiY3XscJMh[XO|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJJJm[2WydH;yJJRz[W6|YXP0bZZifGmxbjDheEAyKHWPIHHmeIVzKDJ2IHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYm= M4D6U|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMEOwNlY{Lz5{MUCzNFI3OzxxYU6=
COS-1 MmG3SpVv[3Srb36gZZN{[Xl? NWrhZ5hHSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBRWEGUZ3HtcYEhdGmpYX7kJIJqdmSrbneg[I9u[WmwIHX4dJJme3OnZDDpckBEV1NvMTDj[YxteyClbz30doFve2[nY4Tl[EB4cXSqIFfhcFQh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBGSzVyPUCuN|nPxE1? NV:1U|hoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxN|A3PDlpPkKxNVMxPjR7PD;hQi=>
CHO MmXOSpVv[3Srb36gZZN{[Xl? MV[yOEBpenN? M3r3SXBienSrYXygZYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDQVGFT\2GvbXGg[ZhxemW|c3XkJIlvKEOKTzDj[YxteyClbz30doFve2[nY4Tl[EB4cXSqIFfhcFQuemW|cH;ud4l3\SCudXPp[oVz[XOnIILldI9zfGW{IIDsZZNucWRiYX\0[ZIhOjRiaILzJIJ6KHS{YX7zZYN1cX[jdHnvckBie3OjeTygSWM2OD1yLkO5{txO NHjiOGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3O|g4PSd-MkGzO|c5PzV:L3G+
COS7 NIeyc5VHfW6ldHnvckBie3OjeR?= NWTsWZVDVW:mdXzheIlwdiCxZjDoeY1idiCSUFHS[4FudWFvTFLEJIV5eHKnc4Pl[EBqdiCjZoLpZ4FvKGe{ZXXuJI1wdmuneTDDU3M4KGOnbHzzJINwNXS{YX7z[oVkfGWmIIfpeIghT2GuNDDhd5Nme3OnZDDhd{Bi[3SrdnH0bY9vKG:oIITyZY5{[WO2aY\heIlwdiCjY4Tpeol1gSCkeTDseYNq\mW{YYPlJIF{e2G7LDDFR|UxRTBwM988US=> MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTh5M{C3NEc,OjF6N{OwO|A9N2F-
Sf21 MlTTSpVv[3Srb36gZZN{[Xl? MVLJcohq[mm2aX;uJI9nKGi3bXHuJGJUTVBiZYjwdoV{e2WmIHnuJJBt[XOvYTDt[Y1jemGwZTD2[ZNq[2ynczDv[kBU\jJzIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhSVSSLXTldIVv\GWwdDDbN2hefGG3cn;jbI9t[XSnIIXweIFs\SxiSVO1NF0xNjQQvF2= MlPOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NkW2NlMoRjJzOU[1OlI{RC:jPh?=
Sf21 MoHxSpVv[3Srb36gZZN{[Xl? MonlTY5pcWKrdHnvckBw\iCVcILh[5VmNUSjd3zlfUBz[XRiQoPldEBmgHC{ZYPz[YQhcW5icHzhd41iKG2nbXLyZY5mKH[nc3njcIV{KG:oIGPmNlEh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDBWHAu\GWyZX7k[Y51KFt|SG30ZZVzd2Oqb3zheIUhfXC2YXvlMEBKSzVyPUNOwG0> M3\Te|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[1OlI{Lz5{MUm2OVYzOzxxYU6=
HepG2 MlXDSpVv[3Srb36gZZN{[Xl? M{DpcVIxKGi{cx?= NXrD[Gw{SWexbnnzeEBi[3Srdnn0fUBifCCJQVy0MZRi\2enZDDoeY1idiCSUFHS[4FudWFibHnnZY5lKGKrbnTpcoch\G:vYXnuJIV5eHKnc4Pl[EBqdiCKZYDHNkBk\WyuczDhd5Nme3OnZDDhd{B1emGwc3HjeIl3[XSrb36gZYZ1\XJiMkCgbJJ{KGK7IHLleIEu\2GuYXP0c5Nq\GG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBGSzVyPUCuOVfPxE1? NI\p[5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkO0NVU4Oyd-MkKzOFE2PzN:L3G+
HEK293 NHTpVVdHfW6ldHnvckBie3OjeR?= NFe0VlUyQCCqcoO= MYnUdoFve2GldHn2ZZRqd25ib3[gbJVu[W5iR1HMOE1nfXOnZDDQVGFT\2GvbXGgcIlo[W6mIHLpcoRqdmdiZH;tZYlvKHS{YX7z[oVkfGWmIHnuJGhGUzJ7MzDj[YxteyCjZoTldkAyQCCqcoOgZpkh\HWjbDDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9NE45|ryP MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzFyMki5NUc,OjNzMEK4PVE9N2F-
COS7 NV3MUG06TnWwY4Tpc44h[XO|YYm= NWTYbVloXHKjboPhZ5RqfmG2aX;uJI9nKEeDTESt[pV{\WRiaIXtZY4hWFCDUnfhcY1iKGyrZ3Hu[EBjcW6maX7nJIRwdWGrbjD0doFve2[nY4Tl[EBqdiCjZoLpZ4FvKGe{ZXXuJI1wdmuneTDDU3M4KGOnbHzzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OD1yLkNOwG0> MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF|MEm2OEc,OjNzM{C5OlQ9N2F-
THP1 NWTlcnlzSW62aXnu[oxidW2jdH;yfUBie3OjeR?= M3PkWFEhcHJ? Mkn6RY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDpckBpfW2jbjDUTHAyKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gVG1CNWmwZIXj[YQhVUOSLUGgd4VkemW2aX;uJJBz\WmwY4XiZZRm\CCob4KgNUBpeiCycnnvdkBRVUFvY3jhcIxmdmenIH3lZZN2emWmIHHmeIVzKDR6IHjyd{BjgSCHTFnTRUwhUUN3ME2xPE45PM7:TR?= MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzhzMUC5Nkc,OjN6MUGwPVI9N2F-
THP1 M2XWcWFvfGmrbn\sZY1u[XSxcomgZZN{[Xl? M3H3cFIhcHK| MkXnRY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDpckBpfW2jbjDUTHAyKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gVG1CNWmwZIXj[YQhVUOSLUGgd4VkemW2aX;uJIlv[3WkYYTl[EBnd3JiMjDodpMheHKrb4KgeI8hWE2DIHPoZYxt\W6pZTDt[YF{fXKnZDDh[pRmeiB5MjDodpMh[nliRVzJV2EtKEmFNUC9NVgvPs7:TR?= NW[wN4Z{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1N|EzOjdpPkK0OVMyOjJ5PD;hQi=>
HEK293 MkHvSpVv[3Srb36gZZN{[Xl? MkPMNVAhfU1? NVfBWnV1OjRiaILz NEXHSYdVemGwc3HjeIl3[XSrb36gc4YhWFCDUj3nZY1u[SBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[XRiMUCgeW0h[W[2ZYKgNlQhcHK|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>? MnXKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OUCwPVAoRjJ2OEmwNFkxRC:jPh?=
HEK293 MofMSpVv[3Srb36gZZN{[Xl? NX3TVo1{OThiaILz MoDpRYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDQVGFT\2GvbXGg[ZhxemW|c3XkJIlvKEiHS{K5N{Bk\WyuczDpcoN2[mG2ZXSg[o9zKDF6IHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGVEPTB;MD6yNe69VQ>? NIrrNGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOzN|g2Oyd-MkWzN|M5PTN:L3G+
COS7 NVj6bHF7TnWwY4Tpc44h[XO|YYm= MoOzWJJidnOjY4TpeoF1cW:wIH;mJIh2dWGwIGDQRXJo[W2vYTDlfJBz\XO|ZXSgbY4hSW[{aXPhckBoemWnbjDtc45s\XliQ1;TO{Bk\WyuczDpcoN2[mG2ZXSgc5Zmem6rZ3j0JIJ6KGS3YXyt[4xwKGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OD1yLkNOwG0> NGTVfFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW5OVc1QSd-Mk[1PVU4PDl:L3G+
THP1 MWLGeY5kfGmxbjDhd5NigQ>? NV\rbFRYOTBidV2= NHPv[G8zPCCqcoO= M1faWnVxemWpdXzheIlwdiCxZjDBRmNCOSCvUl7BJIV5eHKnc4Ppc44hcW5iaIXtZY4hXEiSMTDj[YxteyCjdDCxNEB2VSCjZoTldkAzPCCqcoOgZpkheVCFUjDt[ZRpd2RicnXsZZRqfmVidH:gZ49vfHKxbB?= Mn3oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd{MkCwOlUoRjJ5MkKwNFY2RC:jPh?=
THP1 M2\WNmZ2dmO2aX;uJIF{e2G7 Mni2NVAhfU1? NE[xO2QzPCCqcoO= NWi2c4g6XXC{ZXf1cIF1cW:wIH;mJGFDS0dzIH3SUmEh\XiycnXzd4lwdiCrbjDoeY1idiCWSGCxJINmdGy|IHH0JFExKHWPIHHmeIVzKDJ2IHjyd{BjgSCzUFPSJI1mfGixZDDy[YxifGm4ZTD0c{Bkd262cn;s MoTTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd{MkCwOlUoRjJ5MkKwNFY2RC:jPh?=
COS7 NVjEcZd[TnWwY4Tpc44h[XO|YYm= M2rUdlQzKGi{cx?= MWrUdoFve2GldHn2ZZRqd25ib3[gS2FNPC2odYPl[EBpfW2jbjDQVGFT\2GvbXGgcIlo[W6mIHLpcoRqdmdiZH;tZYlvKGW6cILld5Nm\CCrbjDB[pJq[2GwIHfy[YVvKG2xbnvlfUBEV1N5IHPlcIx{KGGodHXyJFQzKGi{czDifUBlfWGuIHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3ME2wMlXPxE1? NXvVT4t2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1OlAzQDJpPkK3OVYxOjh{PD;hQi=>
COS7 MmXYSpVv[3Srb36gZZN{[Xl? MVq0NkBpenN? MX;UdoFve2GldHn2ZZRqd25iYYSgS4FtPCCodYPl[EBRWEGUZ3HtcYEhVEKGIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGFnemmlYX6g[5Jm\W5ibX;ub4V6KEORU{egZ4VtdHNiYX\0[ZIhPDJiaILzJIJ6KGy3Y3nm[ZJie2ViYYPzZZktKEWFNUC9NE4{Os7:TR?= MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzV4OUG5OUc,Ojd3NkmxPVU9N2F-
COS7 M2LEeGZ2dmO2aX;uJIF{e2G7 MkX6OFIhcHK| MXfUdoFve2GldHn2ZZRqd25ib3[gS4FtPCCodYPl[EBpfW2jbjDQVGFT\2GvbXGgUGJFKGW6cILld5Nm\CCrbjDB[pJq[2GwIHfy[YVvKG2xbnvlfUBEV1N5IHPlcIx{KGGodHXyJFQzKGi{czDifUBlfWGuIHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3ME2wMlM5|ryP M2q0fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUG4PVk1Lz5{N{mxPFk6PDxxYU6=
PC3 NWnPc5NJTnWwY4Tpc44h[XO|YYm= NFnEbWg2OCC3TR?= MnPuNlQhcHK| MY\JcoNz\WG|ZTDpckBxOjFqV1HGNUkheHKxdHXpckBmgHC{ZYPzbY9vKGmwIHj1cYFvKFCFMzDj[YxteyCjdDC1NEB2VSCrbnP1ZoF1\WRiZn;yJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? MkHiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|OUWyNlAoRjJ6M{m1NlIxRC:jPh?=
MDA-MB-231 NF;JZ2VHfW6ldHnvckBie3OjeR?= MX[1NEB2VQ>? NEG5emEzPCCqcoO= MVzJcoNz\WG|ZTDpckBxOjFqV1HGNUkheHKxdHXpckBmgHC{ZYPzbY9vKGmwIHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XRiNUCgeW0hcW6ldXLheIVlKG[xcjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN7NUKyNEc,Ojh|OUWyNlA9N2F-
HEK293 M4C4O2Z2dmO2aX;uJIF{e2G7 MY[yOEBpenN? NIPHTpNVemGwc3HjeIl3[XSrb36gZYN1cX[rdImgZZQhT2GuNDDmeZNm\CCodXzsJIxmdme2aDDoeY1idiCSUFHS[4FudWFiTFLEJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3ME2xMlHPxE1? MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR4NUC5PUc,Ojh2NkWwPVk9N2F-
HEK293 NH7XRphHfW6ldHnvckBie3OjeR?= MkfFOEBpenN? M1f1dnRz[W6|cnXwdoV{e2mxbjDhZ5Rqfmm2eTDheEBpfW2jbjDQVGFT\2GvbXGg[ZhxemW|c3XkJIlvKEiHS{K5N{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGTOSoFteGijIHnu[JVk\WRiTl[tb4FxeGGEIIDyc41wfGW{IHHjeIl3cXS7IIDy[ZRz\WG2ZXSg[o9zKDRiaILzJIZwdGyxd3XkJIJ6KFSQRnHsdIhiKHO2aX31cIF1cW:wIHHmeIVzKDNiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygTWM2OD1{Mt88US=> NUDVRXdqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0OlUxQTlpPkK4OFY2ODl7PD;hQi=>
SCC15 M3HZdmN6fG:2b4jpZ4l1gSCjc4PhfS=> MoTROVAhfU1? NXHuT|dvOjRiaILz M1j2UWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNESzF3IHPlcIx{KHS{YX7z[oVkfGWmIIfpeIghWFCDUnHsdIhiKHOrUl7BJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjdDC1NEB2VSCjZoTldkAzPCCqcoOgZpkhemW|YYr1dolvKHKnZIXjeIlwdiCjc4PhfS=> MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTB|MUC2N{c,OjlyM{GwOlM9N2F-
SCC15 NEXIZnFEgXSxdH;4bYNqfHliYYPzZZk> NI\WRmE2OCC3TR?= M2nxPFI1KGi{cx?= MYXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTR2MyPSClZXzsd{B1emGwc3\lZ5Rm\CC5aYToJHBRSVKkZYThJJNqWk6DIHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBifCB3MDD1UUBi\nSncjCyOEBpenNiYomgdoV{[Xq3cnnuJJJm\HWldHnvckBie3OjeR?= MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTB|MUC2N{c,OjlyM{GwOlM9N2F-
HepG2 Mn:xSpVv[3Srb36gZZN{[Xl? NYW2SlhyOjRiaILz Mmm2RYdwdmm|dDDhZ5Rqfmm2eTDheEBRWEGUZ3HtcYEhcW5iaIXtZY4hUGWyR{KgZ4VtdHNiYYPz[ZN{\WRiYYOgZYN1cX[jdHnvckBw\iCSUGLFJIlv[3WkYYTl[EBnd3JiMkSgbJJ{KGK7IHT1ZYwhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR|UxRTBwMkVOwG0> NU[0SI5rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFE5PDZpPkOwNFAyQDR4PD;hQi=>
HEK293BENA MlHXSpVv[3Srb36gZZN{[Xl? MoDjNlQhcHK| M3LOW3Rz[W6|YXP0bZZifGmxbjDv[kBISUx2LX\1d4VlKGi3bXHuJHBRSVKpYX3tZUB1emGwc3\lZ5Rm\CCrbjDISWszQTOERV7BJINmdGy|IHHmeIVzKDJ2IHjyd{BjgSC|dHXh[Jkh\2yxLXz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3ME2yMlA2O87:TR?= NHm3VXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEO1NVk{Oyd-M{CzOVE6OzN:L3G+
HEK293 MXLGeY5kfGmxbjDhd5NigQ>? Mo\6NVghcHK| NH\mb3FVemGwc3HjeIl3[XSrb36gc4YhcHWvYX6g[pVtdCCuZX7neIghWFCDUnfhcY1iKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[W[2ZYKgNVghcHK|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDiZZNm\CCudX3pcoV{[2WwY3WgZZN{[XluIFXDOVA:OC5zzszN NXXaeHZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzOlI4OzlpPkOwN|YzPzN7PD;hQi=>
293H M4rleGZ2dmO2aX;uJIF{e2G7 MoDTNVYhcHK| MVHUdoFve2GldHn2ZZRqd25ib3[gS2FNPC2GQlSg[pV{\WRiaIXtZY4hWFCDUnfhcY1iKGyrZ3Hu[EBjcW6maX7nJIRwdWGrbjDlfJBz\XO|ZXSgbY4hXUGVLXLsZUBJTUxiMkmzTEBk\WyuczDwdoVqdmO3YnH0[YQh\m:{IEG2JIhzeyCob3zsc5dm\CCkeTDGVmVVKHO3YoP0doF1\SCjZHTpeIlwdiCjbnSgcYVie3W{ZXSgZYZ1\XJiMjDodpMh[nliVGKtSnJGXCCjc4PhfUwhTUN3ME2wMlA6QM7:TR?= MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR{OUC5O{c,OzB2MkmwPVc9N2F-
3T3L1 MX;GeY5kfGmxbjDhd5NigQ>? MVWxNEB2VQ>? M3X5[FI1KGi{cx?= MWfB[49vcXO2IHHjeIl3cXS7IHH0JHBRSVKpYX3tZUBqdiCvb4Xz[UA{XDOOMTDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBCWDFibWLORUBmgHC{ZYPzbY9vKGG2IEGwJJVOKGGodHXyJFI1KGi{czDifUBUYUKUIHfy[YVvKGS7ZTDiZZNm\CCUVD3QR3Ih[W6jbInzbZM> M2\5b|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNUm0OFMzLz5|MEW5OFQ{OjxxYU6=
3T3L1 MnTISpVv[3Srb36gZZN{[Xl? M4HtWVExKHWP MXGyOEBpenN? MUPB[49vcXO2IHHjeIl3cXS7IHH0JHBRSVKpYX3tZUBqdiCvb4Xz[UA{XDOOMTDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBETDN4IH3SUmEh\XiycnXzd4lwdiCjdDCxNEB2VSCjZoTldkAzPCCqcoOgZpkhW1mEUjDndoVmdiCmeXWgZoF{\WRiUmStVGNTKGGwYXz5d4l{ M1XXclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNUm0OFMzLz5|MEW5OFQ{OjxxYU6=
3T3L1 MnfmSpVv[3Srb36gZZN{[Xl? NIj1NpYyOCC3TR?= NEHhVm4zPCCqcoO= MVvB[49vcXO2IHHjeIl3cXS7IHH0JHBRSVKpYX3tZUBqdiCvb4Xz[UA{XDOOMTDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBIdHW2NDDtVm5CKGW6cILld5Nqd25iYYSgNVAhfU1iYX\0[ZIhOjRiaILzJIJ6KFO\QmKg[5Jm\W5iZInlJIJie2WmIGLUMXBEWiCjbnHsfZNqew>? M2XqTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNUm0OFMzLz5|MEW5OFQ{OjxxYU6=
3T3L1 NFXlRmtHfW6ldHnvckBie3OjeR?= NGPL[5UyOCC3TR?= Mle5NlQhcHK| NUT1V5dpSWexbnnzeEBi[3Srdnn0fUBifCCSUFHS[4FudWFiaX6gcY92e2ViM2SzUFEh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iYXTpdI9v\WO2aX6gcXJPSSCneIDy[ZN{cW:wIHH0JFExKHWPIHHmeIVzKDJ2IHjyd{BjgSCVWVLSJIdz\WWwIHT5[UBj[XOnZDDSWE1RS1JiYX7hcJl{cXN? NFL5ZnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEW5OFQ{Oid-M{C1PVQ1OzJ:L3G+
stem cells NYO5W2dHTnWwY4Tpc44h[XO|YYm= NIDITlQ2KGSjeYO= MofqTY5lfWO2aX;uJI9nKGGmaYDv[4Vv\XOrczDpckBpfW2jbjDic45mKG2jcoLve{1l\XKrdnXkJI1me2WwY3j5cYFtKHO2ZX2gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4h[WSrcH;u[YN1cW5icILv[JVkfGmxbjDt[YF{fXKnZDDvckBl[XliNTDpckBxemW|ZX7j[UBw\iCLRGigZpkhTUyLU1GsJGVEPTB;MD6zOe69VQ>? MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODZ5Mk[5PEc,OzB4N{K2PVg9N2F-
HEK293T NFzncpFHfW6ldHnvckBie3OjeR?= M3H1eFE5KGi{cx?= MXfUdoFve2GldHn2ZZRqd25ib3[g[pVtdCCuZX7neIghcHWvYX6gVHBCWmejbX3hNkBmgHC{ZYPz[YQhcW5iSFXLNlk{XCClZXzsd{Bkdy2neIDy[ZN{cW6pIGDQVmUh[W[2ZYKgNVghcHK|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NF0xNjJ3zszN MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODZ5Nke0NUc,OzB4N{[3OFE9N2F-
HEK293T NGn2U3JHfW6ldHnvckBie3OjeR?= MnvGNVghcHK| NGi2UnRVemGwc3HjeIl3[XSrb36gc4Yh[2irbXXybYMhT2GuNDD5[YF{fCCGQlSg[pV{\WRvUGDBVodidW2jIFzCSEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCKRVuyPVNVKGOnbHzzJINwNWW6cILld5NqdmdiUGDSSUBi\nSncjCxPEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwQVAvOzYQvF2= MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODZ5Nke0NUc,OzB4N{[3OFE9N2F-
HepG2 MV3GeY5kfGmxbjDhd5NigQ>? M2THSVMxKHWP M3fMcmJqdmSrbnegZYZncW6rdImgeI8hVkGIMTCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJI1qfG:laH;u[JJq[WxicnXzdIlz[XSrb36gZZQhOzBidV2= MmXXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB5N{CxOVQoRjNyN{ewNVU1RC:jPh?=
HepG2 M120[WZ2dmO2aX;uJIF{e2G7 MXOzNEB2VQ>? NHT2XY1DcW6maX7nJIFn\mmwaYT5JJRwKE6DRkGgbY4hcHWvYX6gTIVxTzJiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBucXSxY3jvcoRzcWGuIILld5BqemG2aX;uJIF1KDNyIIXN MkfBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB5N{CxOVQoRjNyN{ewNVU1RC:jPh?=
COS7 MVPGeY5kfGmxbjDhd5NigQ>? MmPGN|khcHK| MoPJWJJidnOjY4TpeoF1cW:wIH;mJGdidDRvZoXz[YQhcHWvYX6gVHBCWmejbX3hJJRz[W6|ZnXjeIVlKGmwIFPPV|ch[2WubIOgZ48ufHKjboPm[YN1\WRid3n0bEBxT0GONT3UT{1xT0x|IHHu[EBxWmWwbnnscIEuS02YIHnuZ5Vj[XSnZDDmc5IhOzliaILzJIJ6KGS3YXygcJVkcW[ncnHz[UBz\XCxcoTldkBie3OjeTygSWM2OD1zLkVOwG0> NHPNUZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MU[0PFEzPSd-M{G2OFgyOjV:L3G+
K562-IMA[r] M{fDSWZ2dmO2aX;uJIF{e2G7 M3rxeVExKHWP NUHmbHJMPzJiaILz M1W1PWlv\HWldHnvckBw\iC|ZX7zbZRqgmG2aX;uJJRwKGmvYYTpcoljNWmwZIXj[YQh[3m2b4TvfIlkcXS7IHnuJIlu[XSrbnniMZJme2m|dHHueEBpfW2jbjDLOVYzNUmPQWvyYUBk\WyuczDhd5Nme3OnZDDhd{BqdmS3Y4Tpc44hd2ZiY3XscEBl\WG2aDDheEAyOCC3TTDh[pRmeiB5MjDodpMhcW5icILld4Vv[2Vib3[gNUB2VSCrbXH0bY5q[iCkeTDwdo9xcWSrdX2gbY9lcWSnL2TybZRwdi2[MUCwJIR6\SCkYYPl[EBHSUOVIHHuZYx6e2m| NWK3flE6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{G2OFgyOjVpPkOxOlQ5OTJ3PD;hQi=>
Assay
Methods Test Index PMID
Western blot p-VEGFR2 / VEGFR ; Phopsho-RB / RB 29972411 25264247
In vivo Pioglitazone significantly attenuates left ventricular (LV) cavity dilatation and dysfunction by echocardiography as well as LV end-diastolic pressure in mice with extensive anterior myocardial infarction. Pioglitazone partially normalizes LV dP/dt(max) and dP/dt(min), indices of LV contractile function, which are significantly reduced in MI mice. [2] Pioglitazone results in a reduced activation of microglia, reduced induction of iNOS-positive cells and less glial fibrillary acidic protein positive cells in both striatum and substantia nigra pars compacta of MPTP mouse model of Parkinson's disease. Pioglitazone almost completely blocks staining of TH-positive neurons for nitrotyrosine, a marker of NO-mediated cell damage. [3] Pioglitazone (approximately 20 mg/kg/day) attenuates the MPTP-induced glial activation and prevents the dopaminergic cell loss in the substantia nigra pars compacta (SNpc) in MPTP mouse model of Parkinson's disease. [4] Pioglitazone results in a reduction in the number of activated microglia and reactive astrocytes in the hippocampus and cortex of 10-month-old APPV717I transgenic mice. Pioglitazone treatment reduces the expression of the proinflammatory enzymes cyclooxygenase 2 (COX2) and inducible nitric oxide synthase (iNOS). Pioglitazone decreases beta-secretase-1 (BACE1) mRNA and protein levels, and also a 27% reduction in the levels of soluble Abeta1-42 peptide. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 10 mg/mL
(28.05 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 356.44
Formula

C19H20N2O3S

CAS No. 111025-46-8
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04501406 Recruiting Drug: Pioglitazone|Other: Placebo Type 2 Diabetes Mellitus (T2DM)|Nonalcoholic Steatohepatitis University of Florida|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) December 15 2020 Phase 2
NCT04535700 Recruiting Drug: Pioglitazone 30 mg|Other: standard of care Type 2 Diabetes Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal September 18 2020 Phase 4
NCT00904046 Recruiting Drug: Pioglitazone|Drug: Placebo Uric Acid Kidney Stone Disease University of Texas Southwestern Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Takeda Pharmaceuticals North America Inc. September 5 2019 Not Applicable
NCT04671056 Completed Drug: MGL-3196|Drug: Pioglitazone 15mg Healthy Madrigal Pharmaceuticals Inc. November 9 2018 Phase 1
NCT03501277 Completed Drug: Alogliptin|Drug: Pioglitazone|Drug: SYR-322-4833 BL Healthy Volunteers Takeda May 26 2018 Phase 1
NCT03471117 Recruiting Drug: Pioglitazone|Other: Placebo Chronic Kidney Diseases The University of Texas at Arlington|University of Texas Southwestern Medical Center at Dallas April 1 2018 Phase 4

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Pioglitazone (AD-4833) | Pioglitazone (AD-4833) ic50 | Pioglitazone (AD-4833) price | Pioglitazone (AD-4833) cost | Pioglitazone (AD-4833) solubility dmso | Pioglitazone (AD-4833) purchase | Pioglitazone (AD-4833) manufacturer | Pioglitazone (AD-4833) research buy | Pioglitazone (AD-4833) order | Pioglitazone (AD-4833) mouse | Pioglitazone (AD-4833) chemical structure | Pioglitazone (AD-4833) mw | Pioglitazone (AD-4833) molecular weight | Pioglitazone (AD-4833) datasheet | Pioglitazone (AD-4833) supplier | Pioglitazone (AD-4833) in vitro | Pioglitazone (AD-4833) cell line | Pioglitazone (AD-4833) concentration | Pioglitazone (AD-4833) nmr